An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy.
Angel
J B
JB
Department of Medicine, The Ottawa Hospital, Canada.
Khaliq
Y
Y
Monpetit
M L
ML
Cameron
D W
DW
Gallicano
K
K
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D016903:Drug Monitoring; D005260:Female; D017320:HIV Protease Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D019888:Nelfinavir / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019888:Nelfinavir